AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca AZN stock has declined 19.5% in the past six months despite solid underlying financial performance. A key reason…
Barclays Gains 34.2% in a Year: Is There Further Upside Potential?
Shares of Barclays BCS have jumped 34.2% in the past year, underperforming the industry’s 35.1% growth. In the same time…